Crism Therapeutics Corporation

CRTX · AIM · Health Care · mcap £7.0m · 8.8p 1 open situation →

EV: £4.7m
EV / EBIT: –
Net cash: £2.3m
FCF yield: -37.4%
Revenue: –
Share price 1y: −17%
Insiders 12m: no deals
Next report: around 25 Jun

Beta Briefing, track record and signals & risks are not ready for Crism Therapeutics Corporation yet.

We follow 960 UK small caps and every one of their announcements – often hundreds per company. 101 companies are already wired into a briefing: browse them.

Timeline · every situation

dots = announcements

2026 Irinotecan-ChemoSeed glioblastoma Phase 2 Placing of 36% of the market value Placing of 44% of the market value Placing of 22% of the market value

Open · 1

Project milestones

Irinotecan-ChemoSeed glioblastoma Phase 2

Recruiting at lead NHS site since 27 August

Next: First patient dosing in Part 1 dose escalation

21 Sep 2026 Recruiting at lead NHS site since 27 August
26 Jun 2026 Funded; manufacturing done, site activation advanced
25 Mar 2026 First batch made; dosing guided to H1 2026
17 Mar 2026 Registration-grade Phase 2 under way; ODD granted

Open the full view – chart and every step →

Closed · 3

Dilutive fundraisePlacing of 36% of the market value completed · 21 Sep 2026 – 21 Oct 2026 Dilutive fundraisePlacing of 44% of the market value completed · 26 May 2026 – 26 Jul 2026 +0% Dilutive fundraisePlacing of 22% of the market value completed · 10 Dec 2025 – 14 Jan 2026 −4%

Company filings. Not investment advice.